Get the Daily Brief
Latest Biotech News
FDA Clears Urogen’s Zusduri Despite Advisory Panel Doubts
The U.S. Food and Drug Administration approved UroGen’s bladder cancer hydrogel, Zusduri, intended for low-grade, intermediate-risk, non-muscle invasive bladder cancer. Approval comes despite a...
BioNTech Acquires CureVac to Settle mRNA Patent Dispute
BioNTech has agreed to acquire CureVac in a $1.25 billion all-stock transaction, ending years of patent litigation over mRNA vaccine technology. The deal values CureVac’s shares at a 55% premium...
Novel Acute Myeloid Leukemia Combination Shows Promise in Early Trial
A phase 1 trial combining revumenib, an oral menin inhibitor, with standard azacitidine and venetoclax demonstrated high complete remission rates in patients with acute myeloid leukemia harboring...
Physical Exercise Engages Brain Cells to Protect Against Alzheimer’s
Using single-nucleus RNA sequencing, researchers identified that physical activity influences specific hippocampal cell types—microglia and neurovascular-associated astrocytes—in mouse models of...
Rapid Vascular Organoid Generation for Regenerative Medicine
Researchers developed a method to quickly generate vascular organoids from human induced pluripotent stem cells by simultaneous activation of transcription factors ETV2 and NKX3.1. This technique...
FDA Expands Moderna RSV Vaccine Use to Broader Adult Population
The U.S. FDA authorized Moderna’s mRESVIA respiratory syncytial virus vaccine for use in additional adult populations aged 18 to 59 at risk for RSV infection, broadening availability beyond older...
Advancements in AI Improve Neural Network Training Efficiency
Scientists at the Technical University of Munich demonstrated that pretraining artificial neural networks with biological data from mouse retinal waves significantly enhances prediction accuracy...
Industry and Policy Update: Biopharma Investment, Regulatory Shift and Strategic Appointments
Biopharma continues to experience robust public and private financing in 2025, with new IPOs and funding rounds reported. Key regulatory updates include FDA approvals such as Nuvation Bio’s...
Groundbreaking Optical Clock Network Advances Timekeeping Precision
Researchers across six countries conducted the most extensive simultaneous comparison of optical atomic clocks, creating a network spanning thousands of kilometers. This distributed system...
AI-Driven Broad-Spectrum Coronavirus Drug Emerges from Cambridge
A multidisciplinary team at Harvard's Wyss Institute leveraged AI-enabled molecular modeling and physics-based simulations to identify and optimize bemcentinib derivatives with antiviral activity...
Pembrolizumab Approved by FDA for Perioperative Head and Neck Cancer
The U.S. Food and Drug Administration granted approval to pembrolizumab as a perioperative treatment for resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1. This...
FDA Approves UroGen’s Zusduri for Low-Grade Bladder Cancer
Despite a narrowly negative advisory committee vote, the FDA approved UroGen’s hydrogel formulation for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer based on high...
ADC Therapeutics Shutters UK R&D, Cuts Workforce Amid Pipeline Setbacks
ADC Therapeutics is closing its UK research facility, discontinuing several preclinical oncology programs, and cutting its workforce by 30% following the termination of its only clinical-stage...
Pembrolizumab Approval Transforms Head and Neck Cancer Care
The FDA has approved pembrolizumab, an immune checkpoint inhibitor, for resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, following the pivotal phase 3...
Anne Wojcicki Wins 23andMe Asset Auction with Nonprofit Bid
Anne Wojcicki, co-founder and former CEO of 23andMe, secured purchase of the company’s assets for $305 million through her nonprofit, TTAM Research Institute, winning a last-minute auction over...
Insmed’s $750M Follow-On Raised Post-Hypertension Data
Following clinical readouts in hypertension, biopharma firm Insmed announced plans for a $750 million follow-on public offering. The move underscores investor confidence after promising trial...
Novel Vascular Organoids Developed via Dual Transcription Activation
Scientists reported a rapid method to generate functional vascular organoids from human induced pluripotent stem cells by simultaneous activation of endothelial and mural transcription factors,...
Broadening FDA Drug Pricing Negotiations Amid Industry Pushback
The Trump administration is pressuring pharmaceutical companies to negotiate drug prices comparable to other wealthy nations, invoking a 'most-favored nation' clause. Despite awaiting drug and...
New Cooling Technology Promises Energy Efficient Data Centers
Engineers at UC San Diego developed a novel evaporative cooling system employing a porous fiber membrane that passively removes heat from electronics via capillary-driven evaporation. This...
FDA Approves UroGen’s Bladder Cancer Hydrogel Despite Advisory Vote
The FDA cleared UroGen’s hydrogel-based treatment, Zusduri (mitomycin), for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer following positive phase III trial results...